On May 10, 2021, Karges, Johannes; Kalaj, Mark; Gembicky, Milan; Cohen, Seth M. published an article.Reference of [2,2′-Bipyridine]-3,3′-diamine The title of the article was ReI tricarbonyl complexes as coordinate covalent inhibitors for the SARS-CoV-2 main cysteine protease. And the article contained the following:
Since its outbreak, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has impacted the quality of life and cost hundreds-of-thousands of lives worldwide. Based on its global spread and mortality, there is an urgent need for novel treatments which can combat this disease. To date, the 3-chymotrypsin-like protease (3CLpro), which is also known as the main protease, is considered among the most important pharmacol. targets. The vast majority of investigated 3CLpro inhibitors are organic, non-covalent binders. Herein, the use of inorganic, coordinate covalent binders is proposed that can attenuate the activity of the protease. ReI tricarbonyl complexes were identified that demonstrate coordinate covalent enzymic inhibition of 3CLpro. Preliminary studies indicate the selective inhibition of 3CLpro over several human proteases. This study presents the first example of metal complexes as inhibitors for the 3CLpro cysteine protease. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Reference of [2,2′-Bipyridine]-3,3′-diamine
The Article related to rhenium tricarbonyl complex coordinate inhibitor main protease sars cov2, synthesis crystal structure rhenium tricarbonyl complex protease inhibitor 3clpro, sars-cov-2, antiviral agents, bioinorganic chemistry, medicinal inorganic chemistry, protease inhibitor and other aspects.Reference of [2,2′-Bipyridine]-3,3′-diamine